AI in Medicine: Google’s AMIE in The Lancet, Chai and GSK, and an FDA-Cleared Autism Assessment Aid

Three AI-in-medicine stories arrived on 8 and 9 October 2026, each at a very different stage: a first test of a diagnostic chatbot with real patients, a drug-discovery collaboration between companies, and a regulatory clearance for software that helps clinicians. None of this is health advice, and none of it means a machine is now diagnosing anyone on its own.

Google’s AMIE: a supervised feasibility study in The Lancet

Confirmed, peer-reviewed (feasibility stage). The Lancet has published a study led by researchers at Google and Beth Israel Deaconess Medical Center (BIDMC) in Boston, testing AMIE, Google’s research chatbot for medical conversations, with real patients [1][2]. It was a “prospective, single-centre, single-arm feasibility study”: English-speaking adults chatted with AMIE up to five days before an urgent primary care appointment for a single complaint, and “physician safety supervisors monitored all interactions” [1].

What it found. “From April to November, 2025, 114 patients were enrolled with 98 completing both the AMIE interaction and the PCP appointment. Zero conversation safety stops were required on the basis of prespecified criteria. Safety supervisors noted one hallucination and added clinical information in five interactions” [1]. Clinical evaluators rated AMIE’s conversations favourably in “87–100% of cases (17 criteria)”, and patients in “48–96% (16 criteria)” [1]. Doctors filled in surveys in 60 of 98 cases. In the 44 where they had read the AMIE transcript beforehand, they found it helpful for preparing in 33 and said it might have changed their behaviour in 25 [1].

The authors’ own conclusion is cautious. “Although further research is needed, this study shows the initial feasibility of conversational AI in a real-world setting” [1]. Funding is listed as “Alphabet”, Google’s parent; the trial registry names BIDMC as lead sponsor and Google as collaborator [1][3].

Google calls this its “first-ever publication in the main journal of The Lancet” and says summaries helped doctors prepare “in 75% of cases” [2]. That 75% is the 33 of 44 surveyed cases, not three-quarters of all patients.

Chai Discovery and GSK (company-reported)

Company-reported, discovery stage. Chai Discovery, a San Francisco start-up that builds AI models for designing molecules, says GSK “will gain access to Chai’s platform, including its protein folding and design models, to power discovery efforts across GSK’s pipeline” [4]. The deal follows a test: Chai’s models “generated designs to GSK targets, zero-shot without target-specific training”, and GSK’s own lab testing found “binders to all tested targets” [4]. A binder is a designed protein that attaches to a target molecule, an early step towards a possible medicine. GSK’s Christopher Austin said GSK “saw designs with strong binding affinities” [4].

Chai did not say how many targets were tested or share binding data or financial terms. It calls GSK “the latest in a string of collaborations” with large drug makers since the start of 2026 [4]. No drug candidate has been named.

Argus Cognitive’s Neurora: FDA clearance for a clinician’s aid

Confirmed (FDA database). The FDA’s 510(k) database lists Neurora, from Argus Cognitive of Hanover, New Hampshire, as K260064, classified as a “Pediatric Autism Spectrum Disorder Diagnosis Aid”, with a decision of “Substantially Equivalent” on 2 October 2026 [5]. Argus announced it on 8 October [6].

What it does (company-reported). Clinicians upload video and audio from a standard behavioural assessment. Neurora “measures more than 100 vocal, facial and gaze biometrics and reports how closely the child’s behavior aligns with that of children with and without an autism diagnosis” [6]. It is cleared to help clinicians assess children aged 18 months to 12 years and, in its own indications, “is not a stand-alone diagnostic tool” [6]. The release gives no accuracy figures.

What this does not prove

• That AMIE can diagnose patients on its own. Every conversation was supervised, at one clinic, with 98 patients completing; it was not compared against usual care [1].
• That AMIE’s diagnoses are accurate. The Lancet abstract reports safety, conversation quality and experience, not a headline accuracy figure [1].
• That Chai’s designs will become medicines. Binding in a lab test is an early discovery step, and the results are as reported by Chai [4].
• That Neurora diagnoses autism. It is an aid used alongside clinicians’ judgement, and Argus published no performance figures [6].

The Bottom Line

The AMIE study is a careful first step: a supervised, single-site test in which an AI chatbot held safe conversations with real patients by prespecified measures, with one hallucination noted. Chai and GSK are expanding AI protein design work on the strength of an unpublished lab test. Neurora is now FDA-cleared, but only to support a clinician’s diagnosis.

Sources

1. Brodeur, Koshy, Palepu et al. (48 authors), “Conversational diagnostic artificial intelligence in ambulatory primary care: a prospective feasibility study”, The Lancet, available online 8 October 2026, DOI 10.1016/S0140-6736(26)01535-7 (peer-reviewed; the Lancet site blocked direct access, so the abstract was read on Google Research’s publication page; journal, date and DOI confirmed via Crossref and Elsevier metadata). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01535-7/abstract (abstract mirror: https://research.google/pubs/a-prospective-clinical-feasibility-study-of-a-conversational-diagnostic-ai-in-an-ambulatory-primary-care-clinic/)
2. Mike Schaekermann, “Study: AI could improve patient-physician relationships”, Google blog, 8 October 2026 (company post; company framing). https://blog.google/innovation-and-ai/technology/health/amie-clinical-study-lancet/
3. ClinicalTrials.gov, NCT06911398, “AMIE’s Clinical Conversational Abilities in an Urgent Care Setting” (trial registry; read 9 October 2026). https://clinicaltrials.gov/study/NCT06911398
4. Chai Discovery, “Chai Discovery Announces Collaboration with GSK Following Successful Wet-Lab Evaluation”, Business Wire, 9 October 2026, 8:01 a.m. EDT (13:01 BST) (company release, includes GSK quote). https://www.businesswire.com/news/home/20261009951102/en/ (text read via https://www.financialcontent.com/article/bizwire-2026-10-9-chai-discovery-announces-collaboration-with-gsk-following-successful-wet-lab-evaluation)
5. US Food and Drug Administration, 510(k) Premarket Notification database, K260064, Neurora, Argus Cognitive, Inc., decision date 2 October 2026 (regulator record). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K260064
6. Argus Cognitive, “FDA Clears Argus Cognitive’s Neurora to Support Autism Diagnosis in Children Ages 18 Months Through 12 Years”, Business Wire, 8 October 2026, 8:12 a.m. EDT (13:12 BST) (company release). https://www.businesswire.com/news/home/20261008763773/en/ (text read via https://www.financialcontent.com/article/bizwire-2026-10-8-fda-clears-argus-cognitives-neurora-to-support-autism-diagnosis-in-children-ages-18-months-through-12-years)